Voluntary market withdrawal: Oxbryta (Pfizer – October)

Oct. 2024Pharmacy Updates

Pfizer Inc. is withdrawing Oxybryta from the market. Oxbryta is used for the treatment of sickle cell disease in adults and children 12 years old and older. Sickle cell disease affects the shape of red blood cells, which carry oxygen to all parts of the body.

This drug is being withdrawn from the market because recent data show the benefit of taking Oxbryta does not outweigh the risks. In clinical trials, there was a larger number of patients with severe pain because of less blood flow.

The Food and Drug Administration (FDA) has been conducting a safety review of Oxybryta and will communicate any additional findings when the review is complete. The FDA encourages health care professionals and patients to report adverse events or quality problems experienced with the use of Oxbryta.

There are other FDA-approved medications for the treatment of sickle cell disease. The FDA advises that you should contact your doctor or health care professional about stopping Oxbryta and starting another treatment option.

To learn more about this recall, you can take one or more of the steps below.

  • Talk to your doctor or pharmacist.
  • Visit the FDA website.

Recent Announcements

Voluntary nationwide recall: Sucralfate (Nostrum – July)

Nostrum Laboratories, Inc. is recalling all lots of Sucralfate Tablets USP 1 gram. Sucralfate is used for the prevention and treatment of certain stomach ulcers.
Jul. 2025Pharmacy Updates

Receive consultations to better support the behavioral health needs of child and adolescent patients

The Telephonic Psychiatric Consultation Service Program (TiPS) is a Pennsylvania HealthChoices program that gives primary care providers access to free, on-demand consultations with child and adolescent psychiatrists, typically within 30 minutes. It is available to providers of children and adolescents who have Pennsylvania Medicaid, Children’s Health Insurance Program, or UPMC Health Plan commercial insurance.
Jul. 2025What's New

Voluntary nationwide recall: Sucralfate (Nostrum – July)

Nostrum Laboratories, Inc. is recalling all lots of Sucralfate Tablets USP 1 gram. Sucralfate is used for the prevention and treatment of certain stomach ulcers.
Jul. 2025Pharmacy Updates